Quiet on the insider front: nobody at Champions Oncology, Inc. bought or sold CSBR shares with their own money this past year.
No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters. Big money check: 28 institutions held CSBR as of Q2 2026, and more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jan 16, 2024 | Mendelson Daniel Newman | Director | Buy | 1,000 | $6.50 | $6K | SEC |
| Jan 12, 2024 | Mendelson Daniel Newman | Director | Buy | 2,000 | $6.27 | $13K | SEC |
| Jan 11, 2024 | Mendelson Daniel Newman | Director | Buy | 2,944 | $6.31 | $19K | SEC |
| Jan 10, 2024 | Mendelson Daniel Newman | Director | Buy | 3,000 | $6.25 | $19K | SEC |
| Jan 9, 2024 | Mendelson Daniel Newman | Director | Buy | 1,000 | $6.15 | $6K | SEC |
| Jan 8, 2024 | Mendelson Daniel Newman | Director | Buy | 2,000 | $6.09 | $12K | SEC |
| Jan 8, 2024 | Mendelson Daniel Newman | Director | Buy | 3,000 | $6.12 | $18K | SEC |
| Jan 4, 2024 | Mendelson Daniel Newman | Director | Buy | 500 | $5.83 | $3K | SEC |
| Dec 26, 2023 | Mendelson Daniel Newman | Director | Buy | 2,500 | $4.92 | $12K | SEC |
| Dec 21, 2023 | Mendelson Daniel Newman | Director | Buy | 2,100 | $4.82 | $10K | SEC |
| Dec 20, 2023 | Mendelson Daniel Newman | Director | Buy | 5,000 | $4.75 | $24K | SEC |
| Oct 16, 2023 | Mendelson Daniel Newman | Director | Buy | 4,000 | $6.16 | $25K | SEC |
| Oct 16, 2023 | Mendelson Daniel Newman | Director | Buy | 5,000 | $6.22 | $31K | SEC |
| Oct 16, 2023 | Mendelson Daniel Newman | Director | Buy | 1,500 | $5.95 | $9K | SEC |
| Oct 13, 2023 | Mendelson Daniel Newman | Director | Buy | 5,000 | $6.40 | $32K | SEC |
Price and valuation, revenue and profit by quarter, who owns it, dilution, earnings timing and a written bull & bear case, in one report you can also print or save as a PDF. Here is what each section looks like (screenshots from a real report):
Price, market cap, P/E, revenue and profit growth at a glance.
A written read of everything below: what supports the stock, what worries.
A 0-100 score with the reasons, plus earnings date, volatility and analyst ratings (Analyst).
Three years of results from SEC filings, growth marked quarter by quarter.
Streaks like “7 quarters of net selling” spotted for you.
Top funds, who added, who cut and who sold out last quarter.
Every House and Senate trade in the stock, late filers flagged.
Stock offerings, shelf registrations and share-count growth, scored.
Day trading, swing trading and long-term numbers side by side.
Free plan: insider trades, insider signal and Congress trades. Sections marked Scout or Analyst unlock with that plan (from $29/month). Screenshots: Micron Technology report, Oct 19, 2026.
There were no open-market insider trades in CSBR in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
28 investment managers reported holding CSBR in SEC Form 13F filings for Q2 2026.
No congressional trades in CSBR were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).